Return On Equity
65%
Trailing 12 months · Through 30 Sep 2025
YoY relative change: -39%
Sigyn Therapeutics, Inc. financial metrics
Period Q3 2025 · Filed 14 Nov 2025
Key metrics snapshot
Return On Assets
-417%
Third-party reference; reporting period not verified
Operating Margin
0%
Third-party reference; reporting period not verified
Current Ratio
0.02x
Third-party reference; reporting period not verified
Quick Ratio
0.02x
Third-party reference; reporting period not verified
Debt-to-equity
-1.03x
Period-end balance · Through 30 Sep 2025
YoY relative change: -5.6%
NetIncomeLoss YoY
19%
Trailing 12 months · Through 30 Sep 2025
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
65%
Trailing 12 months · 30 Sep 2025
|
-39% |
| Return On Assets |
-417%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
0%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.02x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
0.02x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
-1.03x
Period-end balance · 30 Sep 2025
|
-5.6% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
19%
Trailing 12 months · 30 Sep 2025
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
1,605,377
Period-end balance · 05 Sep 2025
|
|
| Common Stock, Shares, Outstanding |
1,605,377
Period-end balance · 30 Sep 2025
|
+13% |
| Common Stock, Value, Issued |
$161
Period-end balance · 30 Sep 2025
|
+13% |
| Weighted Average Number of Shares Outstanding, Basic |
1,605,377
Reported period · 30 Sep 2025
|
+27% |
| Weighted Average Number of Shares Outstanding, Diluted |
1,605,377
Reported period · 30 Sep 2025
|
+27% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$773,604
Period-end balance · 30 Sep 2025
|
+26% |
| Additional Paid in Capital |
$11,462,608
Period-end balance · 30 Sep 2025
|
+12% |
| Assets |
$135,571
Period-end balance · 30 Sep 2025
|
-68% |
| Assets, Current |
$85,571
Period-end balance · 30 Sep 2025
|
-68% |
| Cash and Cash Equivalents, at Carrying Value |
$85,571
Period-end balance · 30 Sep 2025
|
-48% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2025
|
0% |
| Common Stock, Shares Authorized |
100,000,000
Period-end balance · 30 Sep 2025
|
-90% |
| Common Stock, Shares, Issued |
1,605,377
Period-end balance · 30 Sep 2025
|
+13% |
| Depreciation |
$2,724
Trailing 12 months · 30 Sep 2025
|
-54% |
| Earnings Per Share, Basic |
-1
Trailing 12 months · 30 Sep 2025
|
+39% |
| Earnings Per Share, Diluted |
-1
Trailing 12 months · 30 Sep 2025
|
+39% |
| General and Administrative Expense |
$1,701,601
Trailing 12 months · 30 Sep 2025
|
-8.7% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$3,221,072
Trailing 12 months · 30 Sep 2025
|
+19% |
| Liabilities |
$6,052,780
Period-end balance · 30 Sep 2025
|
+39% |
| Liabilities and Equity |
$135,571
Period-end balance · 30 Sep 2025
|
-68% |
| Liabilities, Current |
$3,989,491
Period-end balance · 30 Sep 2025
|
-6.7% |
| Nonoperating Income (Expense) |
$1,340,964
Trailing 12 months · 30 Sep 2025
|
-8.6% |
| Operating Income (Loss) |
$1,880,108
Trailing 12 months · 30 Sep 2025
|
+32% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.1
Period-end balance · 30 Sep 2025
|
0% |
| Other Assets, Noncurrent |
$50,000
Period-end balance · 30 Sep 2025
|
+141% |
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2025
|
0% |
| Preferred Stock, Shares Authorized |
10,000,000
Period-end balance · 30 Sep 2025
|
0% |
| Research and Development Expense |
$140,101
Trailing 12 months · 30 Sep 2025
|
-84% |
| Retained Earnings (Accumulated Deficit) |
$17,379,978
Period-end balance · 30 Sep 2025
|
-23% |
| Stockholders' Equity Attributable to Parent |
$5,917,209
Period-end balance · 30 Sep 2025
|
-51% |
Comparisons, sources and research notes
Sources and sharing
SIGY - Sigyn Therapeutics, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2025
- Latest reported value
- Return On Equity 65%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2025.
- Most recent SEC facts end date on this page: 30 Sep 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for SIGY - Sigyn Therapeutics, Inc.
Latest financial period: Q3 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
14 Nov 2025
Page type
Company facts
Latest period
Q3 2025
SEC-backed company facts were refreshed from filings filed on 14 Nov 2025.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 39% versus the comparable prior period.
Compared with
Compared with Sigyn Therapeutics, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2025.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- SIGY - Sigyn Therapeutics, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2025.
- Headline metric: Return On Equity 65%.
Change
- Return On Equity YoY relative change: -39%.
- Most recent SEC facts end date: 30 Sep 2025.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2025-09-30) highlights Return On Equity 65.5%, Return On Assets -417.4%, and Operating Margin 0.0%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-33710%
fair value gap
Fair value per share
$8.40
Market price
$0.0250
SIGY - Local security
PEG ratio
n/a
Enterprise value
$13.57M
Equity value
$13.49M
DCF fair value scenarios
Bear
$6.26
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -25131%
Base
$8.40
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -33710%
Bull
$11.78
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -47220%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Local security market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
n/a
Local security market cap / SEC revenue
Revenue is unavailable or not positive
P/B
n/a
Local security market cap / SEC equity
Equity is unavailable or not positive
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $932.1K
- Trailing SEC FCF
- Reported FCF
- $932.1K
- Net income
- $3.22M
- EBITDA
- $1.88M
- Cash
- $85.6K
- Debt
- n/a
- Equity
- $5.92M
- Shares
- 1,605,377
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: earnings per share is not positive
Compare This Company Through SEC-backed Metrics
Use these links to compare SIGY - Sigyn Therapeutics, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: 19%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
36.1/100
Weak Confidence medium
Return On Equity
65%
Metric score 100.0/100
Return On Assets
-417%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.02x
- Quick Ratio
- 0.02x
- Debt to Equity
- -1.03x
Strengths
Return On Equity and NetIncomeLoss YoY
Watchpoints
Return On Assets, Operating Margin, and Current Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first